<DOC>
	<DOCNO>NCT00377481</DOCNO>
	<brief_summary>This study ass comfort subcutaneous injection NeoRecormon darbepoetin alfa ( Aranesp ) patient renal anemia . Eligible patient randomize receive comparable subcutaneous injection either darbepoetin alfa ( 30 microgram ) NeoRecormon ( 6000IU ) . They cross alternative treatment arm treatment . After injection pain assess use visual analogue scale ( VAS ) 6-point verbal rating scale ( VRS ) , patient preference assess . The anticipated time study treatment &lt; 3 month , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>COMFORT Study : A Crossover Study NeoRecormon ( Epoetin Beta ) Darbepoetin Alfa Patients With Renal Anemia .</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>adult patient , &gt; 18 year age ; patient renal anemia posttransplant anemia . poorly controlled hypertension ; know hypersensitivity NeoRecormon darbepoetin alfa .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>